The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Also on stage in Chicago in the coming weeks, the first national tour of “Stereophonic” and David Byrne’s much-anticipated ...

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common ...